Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE IrriMax Corporation
Innovative Irrigation Product Company Excited to Participate And Support SIS 34th Annual Meeting
ATLANTA, May 16, 2014 /PRNewswire/ -- Surgical Infection Society members attended an opening day continuing medical education (CME) lunch symposium sponsored by IrriMax Corporation, the makers of IRRISEPT, the first and only FDA-cleared cleansing and debridement system containing 0.05% Chlorhexidine Gluconate (CHG) for irrigation.
A three member panel of distinguished surgeons, Dr. Donald Fry, Dr. Nick Namias and Dr. Kamal Itani presented a CME/CE accredited program entitled "Local Measures to Prevent SSI".
Dr. Itani reviewed clinical evidence related to pre-operative skin preparation. Dr. Namias addressed the clinical evidence surrounding the merits of primary closure vs. delayed primary closure. Dr. Fry reviewed studies regarding topical use of antibiotics in surgical wounds and described a planned multi-center trial on surgical irrigation with 0.05% CHG. The panel presentation will be published in Surgical Infections, the official journal of the Surgical Infection Society (SIS).
IrriMax was excited to sponsor this important panel discussion. The company's main corporate goal is to help treat and prevent infections, help improve patient outcomes and drive positive impact to healthcare economics regarding surgical infections.
"We believe it's important to work closely with key professional societies, such as SIS. With our focus on reducing Surgical Site Infections, it is critical that we engage with the experts in this field, to collaborate and learn from them," said Gareth Clarke, CEO of IrriMax Corporation.
The company's VP Clinical Affairs, Carolyn Twomey, stated, "SIS members represent those surgeons who are on the cutting edge of research, technology and education regarding surgical infections and improving surgical patient outcomes." She went on to say, "We are getting ready to launch a multi-center, randomized, controlled, clinical trial with IRRISEPT. Corporately, we are driving a rigorous, world-class clinical program and it's imperative to support and partner in these events. Most, if not all, of the principal investigators in our trial are members of SIS and many are attending this conference."
IrriMax® Corporation develops and markets cleansing, debridement and irrigation solutions using a patented, innovative delivery method. Continual innovation and ongoing clinical research guide the development of IrriMax products. For more information visit www.irrisept.com.
Corporate Headquarters 770-807-3355
©2012 PR Newswire. All Rights Reserved.